Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications
T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
567 Merkel cell carcinomas are infiltrated by tumor-associated macrophages that counteract intratumoral CD8 T-cell benefit and correlate with resistence to PD-1 pathway blockade
Utility of a circulating tumor DNA test for detecting clinically evident and occult Merkel cell carcinoma
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
How We Treat Merkel Cell Carcinoma: Within and Beyond Current Guidelines
Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer
Response to “Mohs surgery for early‐stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision +/− radiation therapy with no increase in MCC‐specific death”
675 Utility of circulating tumor DNA testing in Merkel cell carcinoma patients
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Immune checkpoint inhibitors to treat cutaneous malignancies
Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Tuberculosis following PD-1 blockade for cancer immunotherapy
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma